STOCKS TELEGRAPH

Tag: ORTX stock price

  • Orchard Therapeutics (ORTX) Stock: What’s Happening Today?

    Orchard Therapeutics (ORTX) Stock: What’s Happening Today?

    Orchard Therapeutics plc (ORTX) is experiencing a remarkable surge in its market performance today, exhibiting a substantial gain of 97.77% and reaching a trading price of $15.98 at the latest trades.

    Additionally, the trading activity for Orchard Therapeutics stock has witnessed an atypical surge in volume, with over 6 million shares changing hands within the initial hour of the trading session. This notable surge contrasts sharply with the typical trading volume of 47.58K shares.

    The upswing in Orchard Therapeutics (ORTX) stock value coincides with the unveiling of an acquisition proposal. Kyowa Kirin, a leading Japanese pharmaceutical company, is set to acquire ORTX in a definitive agreement worth approximately $477.6 million.

    This acquisition aligns with Kyowa Kirin’s 2030 Vision, emphasizing innovative medical solutions and its commitment to life-changing medicines, particularly in rare diseases.

    Orchard Therapeutics’ gene therapy approach using genetically modified hematopoietic stem cells is at the forefront of genetic medicine, complementing Kyowa Kirin’s expertise. This strategic move will accelerate the development of ORTX’s MPS programs and other research initiatives.

    The combination of Orchard’s technology and Kyowa Kirin’s resources positions them to advance biopharmaceutical candidates across various therapeutic areas, including oncology and autoimmune diseases, with the potential to revolutionize medical care.

    In accordance with the established agreement, Kyowa Kirin is poised to orchestrate the acquisition of Orchard Therapeutics’ American Depositary Shares (ADSs) at a notable price of $16.00 per ADS in cash, amounting to approximately $387.4 million or ¥57.3 billion in value.

    This proposition represents a substantial premium of 144% over ORTX’s 30-day volume-weighted average ADS price leading up to October 4.

    As part of this transaction, Orchard Therapeutics (ORTX) shareholders will receive a non-transferable Contingent Value Right (CVR), entitling them to a cash payment of $1.00 per ADS, contingent on the approval of OTL-200 for Metachromatic Leukodystrophy (MLD) treatment in the United States, as explicitly outlined in the CVR Agreement.

  • Orchard Therapeutics plc (ORTX) stock is jumping to 11.43% – Here’s why?

    Orchard Therapeutics plc (ORTX) stock is jumping to 11.43% – Here’s why?

    Orchard Therapeutics plc (ORTX) has seen an increase of 11.43% in the aftermarket because the company announced an agreement with National Health Service. However, the last trading session concluded at $1.05 with a decrease of 3.67%.

    Agreement of ORTX with National Health Service – What’s happening?

    ORTX announced on 3rd February 2022 that it has made an agreement with National Health Service. The agreement is based on evaluation determination from the National Institute for Health and Care Excellence (NICE), which will recognize Libmeldy’s clinical impact and economic value. In addition, the business reported the first two commercially treated patients in Germany and France who were able to take advantage of early access reimbursement arrangements. Lastly, a third Middle Eastern patient was referred to an Italian hospital for international paid therapy.

    Publication in The Lancet – What is it?

    On 21st January 2022, ORTX reported the publication of long-term clinical results testing the safety and efficacy of Libmeldy in The Lancet. The treatment with Libmeldy resulted in persistent, clinically important benefits in patients with developmental MLD. Moreover, these are encouraging findings that demonstrate the potential of the HSC gene therapy technique to treat severe genetic disorders with a particular procedure. Lastly, the company is launching Libmeldy throughout Europe and plans to pursue regulatory permissions in the future.

    What’s Next?

    Libmeldy is a game-changer in the therapy of MLD. These findings underscore the potential long-term advantages of HSC gene therapy for children, particularly when treatment is initiated before symptoms appear.

    Commercial and Regulatory Progress for HSC Gene Therapy Programs by ORTX

    On 10th January 2022, ORTX stated the commercial and regulatory progress of gene therapy programs at the virtual 40th Annual J.P. Morgan Healthcare Conference. Looking back on 2021, Orchard has made a lot of progress, from showing improvement with the release of Libmeldy in Europe to gaining clarity from regulators on the possible route forward for the MLD, WAS, and MPS-IH programs.

    Not only this but the company has also worked on displaying major discovery initiatives through the HAE partnership with Pharming. Lastly, ORTX is starting 2022 with the same passion and dedication to continue growing a firm focused on transforming the medical paradigm for patients with severe genetic illnesses.